Atlas Trials

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Clinical trial NCT05998642 · RECRUITING

Trial details

NCT number
NCT05998642
Sponsor
Canadian Cancer Trials Group
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non-hodgkin Lymphoma
Start date
2024-02-13
Primary completion
2028-05-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.